Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: Results of a European, multicenter cohort study

Supportive Care in Cancer

Volumn 22, Issue 2, 2014, Pages 417-426

  Jordan, Karin ^a   Proskorovsky, Irina ^b   Lewis, Philip ^d   Ishak, Jack ^b   Payne, Krista ^c   Lordan, Noreen ^e   Kyriakou, Charalampia ^f   Williams, Cathy D ^g   Peters, Sarah ^h   Davies, Faith E ⁱ  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b Modeling and Simulation   (Canada)

^c UNITED BIOSOURCE CORPORATION   (Canada)

^d Celgene GmbH   (Germany)

^e UNITED BIOSOURCE CORPORATION   (United States)

^f NORTHWICK PARK HOSPITAL   (United Kingdom)

^g NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^h Celgene Corporation   (United Kingdom)

ⁱ ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adverse events; Health related quality of life; Multiple myeloma; Symptoms

Indexed keywords

ALKYLATING AGENT; BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE;

ABDOMINAL PAIN; ADULT; ANOREXIA; ARTICLE; ASTHENIA; BLURRED VISION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER PAIN; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL FEATURE; COHORT ANALYSIS; CONFUSION; CONSTIPATION; CROSS-SECTIONAL STUDY; DEHYDRATION; DEMOGRAPHY; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DYSPEPSIA; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; FRACTURE; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; GERMANY; HEALTH CENTER; HUMAN; HYPESTHESIA; HYPOTENSION; INSOMNIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MM MODULE QUESTIONNAIRE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PARESTHESIA; PERIPHERAL EDEMA; PNEUMONIA; POLYDIPSIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE QUESTIONNAIRE CORE 30; SOMNOLENCE; SYMPTOM ASSESSMENT; TREMOR; UNITED KINGDOM; UPPER RESPIRATORY TRACT INFECTION;

AGED; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DEPRESSION; FEMALE; GERMANY; GREAT BRITAIN; HUMANS; MALE; MULTIPLE MYELOMA; QUALITY OF LIFE; QUESTIONNAIRES; SOCIOECONOMIC FACTORS;

EID: 84896028296     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-1991-4     Document Type: Article

References (32)

1. Surveillance Epidemiology and End Results. National Cancer Institute. http://seer.cancer.gov/. Accessed 25 February 2013
2. Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, Møller H, Consultant Haematologists, South Thames Haematology Specialist Committee (2004) A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 127:299-304 (Pubitemid 39468943)
3. International Agency for Research on Cancer. Cancer Mondial GLOBOCAN 2008 Database. http://www-dep.iarc.fr/. Accessed 25 February 2013
4. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, Greipp PR, Kyle RA, Gertz MA (2008) Improved survival in multiple myeloma and the impact of novel therapies. Blood 111:2516-2520
5. Palumbo A, Attal M, Roussel M (2011) Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival. Clin Cancer Res 17:1253-1263
6. Larocca A, Palumbo A (2011) Evolving paradigms in the treatment of newly diagnosed multiple myeloma. J Natl Compr Canc Netw 9:1186-1196
7. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, San Miguel J, Hellmann A, Facon T, Foà R, Corso A, Masliak Z, Olesnyckyj M, Yu Z, Patin J, Zeldis JB, Knight RD, Multiple Myeloma (010) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123-2132 (Pubitemid 350146107)
8. Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM (2009) Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23:2147-2152
9. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC (2007) Extended follow-up of a phase 3 trial in relapsedmultiplemyeloma: final time-to-event results of the APEX trial. Blood 110:3557-3560 (Pubitemid 350159621)
10. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC, Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487-2498 (Pubitemid 41007864)
11. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer EA, Siegel D, Borrello I, Rajkumar SV, Chanan-Khan AA, Lonial S, Yu Z, Patin J, Olesnyckyj M, Zeldis JB, Knight RD, Multiple Myeloma (009) Study Investigators (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133-2142 (Pubitemid 350146108)
12. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, Renaud M, Harousseau JL, Guillerm G, Chaleteix C, Dib M, Voillat L, Maisonneuve H, Troncy J, Dorvaux V, Monconduit M, Martin C, Casassus P, Jaubert J, Jardel H, Doyen C, Kolb B, Anglaret B, Grosbois B, Yakoub-Agha I, Mathiot C, Avet-Loiseau H, Intergroupe Francophone du Myélome (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370:1209-1218 (Pubitemid 47516593)
13. Hulin C, Facon T, Rodon P, Pegourie B, Benboubker L, Doyen C, Dib M, Guillerm G, Salles B, Eschard JP, Lenain P, Casassus P, Azaïs I, Decaux O, Garderet L, Mathiot C, Fontan J, Lafon I, Virion JM, Moreau P (2009) Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 27:3664-3670
14. Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259-2266
15. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG, VISTA Trial Investigators (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917
16. Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12:431-440
17. Farquhar-Smith P (2011) Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care 5:1-7
18. Durie BG (2005) New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 6:181-190
19. Wisløff F, Gulbrandsen N (2000) Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta Oncol 39:809-813
20. Uyl-de Groot CA, Buijt I, Gloudemans IJ, Ossenkoppele GJ, Berg HP, Huijgens PC (2005) Health related quality of life in patients with multiple myeloma undergoing a double transplantation. Eur J Haematol 74:136-143 (Pubitemid 40175318)
21. Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J, EORTC Quality of Life Group (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43: 1670-1678 (Pubitemid 47042371)
22. Kvam AK, Fayers P, Wisloff F (2010) What changes in health-related quality of life matter to multiple myeloma patients? A prospective study. Eur J Haematol 84:345-353
23. Williams CD, Proskorovsky I, Lewis P, Ishak KJ, Payne KA, Lordan N, Kyriakou C, Davies F, Peters S, Jordan K (2010) Components of Global Quality of Life in multiple myeloma [abstract]. Blood 116:4735
24. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A (2001) The EORTC QLQ-C30 Scoring Manual, 3rd edn. EORTC Quality of Life Group, Brussels
25. Molassiotis A, Wilson B, Blair S, Howe T, Cavet J (2011) Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners. Psychooncology 20:88-97
26. Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860-1867 (Pubitemid 47557312)
27. Lee SJ (2004) Patient-reported outcomes inmultiple myeloma. J Natl Compr Canc Netw 2:379-383
28. Poulos AR, Gertz MA, Pankratz VS, Post-White J (2001) Pain, mood disturbance, and quality of life in patients with multiple myeloma. Oncol Nurs Forum 28:1163-1171
29. Kirkova J, Walsh D, Aktas A, Davis MP (2010) Cancer symptom clusters: old concept but new data.Am J Hosp Palliat Care 27:282-288
30. Cheng KK, Lee DT (2011) Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol 78:127-137
31. Delforge M, Dhawan R, Robinson D Jr, Meunier J, Regnault A, Esseltine DL, Cakana A, van de Velde H, Richardson PG, San Miguel JF (2012) Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial. Eur J Haematol 89:16-27
32. Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P (2012) Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 26:595-608